Azulene Labs has raised $3.4 million in a pre-seed funding round to develop physics-based AI models aimed at drug discovery, materials development and industrial chemistry. The company says its models use quantum-mechanical training data to improve the accuracy and efficiency of molecular simulations compared with existing AI approaches.
Azulene Labs’ approach
Azulene says its physics-based foundation models deliver roughly 100 times the efficiency of competitors while being at least 200 times more cost-effective. According to the company, training on quantum-mechanical data yields higher-quality data and higher-accuracy AI models for the same amount of capital as other approaches, and its models are constrained to the laws of physics in ways that current cutting-edge AI models are not.
“An airplane is specified down to manufacturing tolerances before anyone builds a prototype. A skyscraper is load-tested in simulation before a single beam goes up. These ‘macroscopic’ models are so accurate that you can put enormous trust in them. Chemistry has had nothing like this. Until now,” says Azulene Labs co-founder Nicolas Sawaya.
Sawaya, who holds a PhD in chemical physics from Harvard, founded Azulene Labs after leading quantum algorithm development for chemistry at Intel Labs. The founding team includes scientists with PhDs from Caltech, Harvard, UC Berkeley, Columbia, and MIPT.
Funding, customers and use of proceeds
The $3.4 million pre-seed round was led by Ground State Ventures, with participation from existing investor Entrada Ventures and angel investors. Azulene plans to use the funding to expand its team and advance product development as it works with biotechnology and industrial chemistry customers.
The company positions its technology as applicable across pharma, agriculture, energy storage, plastics and industrial chemicals. Sawaya highlighted potential impacts, saying, “Imagine cancer medicines aimed at proteins the industry wrote off as undruggable decades ago; new antibiotics for infections that have stopped responding to everything we have; replacements for the solvents the chemical industry runs on by the megaton, many of which are toxic enough that regulators are phasing them out with no good substitute yet found, or plastics that perform like the ones we use today but break down completely afterward instead of persisting for centuries.”
Ton van ‘t Noordende, founder and General Partner at Ground State Ventures, commented: “What we see in this company is exceptional founder-market fit at a time when the pharma market is hungry for exactly what this incredible team is building. Nicolas is the perfect person to lead Azulene Labs to become the Anthropic of chemistry.”
